Browse the evidence

Incretin medications (GLP-1 RAs and dual agonists) are the most effective class of AOMs for older adults, achieving 15-25% weight loss, but require careful titration to manage side effects.

Incretin drugs like Semaglutide and Tirzepatide are currently the most effective weight loss medications for older adults, often resulting in 15-25% body weight loss. They work by mimicking gut hormones to reduce hunger. Doctors usually start with a low dose to minimize side effects like nausea and gradually increase it.

Achieving a 5% weight loss over one year results in substantial direct medical cost savings for people with obesity, with savings increasing alongside higher obesity severity.

You do not need to achieve massive weight loss to see financial benefits. Losing just 5% of your body weight within a year can lead to substantial savings in direct medical costs, with the greatest savings seen in those with higher obesity severity (Class II and III). Focus on achieving this modest, sustainable reduction.

Phentermine/topiramate and naltrexone/bupropion are effective alternative pharmacotherapies for weight loss (4-10%) in patients without cardiovascular contraindications, offering oral administration options.

If you cannot take or afford weekly injections, oral medications like phentermine/topiramate or naltrexone/bupropion are effective alternatives. They typically result in 4-10% weight loss. Side effects like nausea or insomnia are common but often improve over time, especially if you start with a low dose and increase slowly. These are not suitable if you have heart disease, high blood pressure, or a history of seizures.

Resistance training over a full range of motion is superior to partial range of motion for hypertrophy.

To build the most muscle, perform your exercises through a full range of motion. Partial reps are less effective for hypertrophy.

Supplementation with 5g/day spinach-derived thylakoid membranes combined with a hypo-caloric diet significantly improves atherogenic indices (AIP, CRI-I, CRI-II) and insulin resistance surrogates (TyG-BMI, METS-IR) in obese women with PCOS compared to placebo.

If you have PCOS and are overweight, adding 5 grams of spinach thylakoid extract daily to your calorie-restricted diet may help improve your blood vessel health markers and insulin sensitivity more than dieting alone. Take it 30 minutes before lunch.

Tirzepatide (5, 10, or 15 mg once weekly) provides significantly longer continuous time in glycaemic control (HbA1c <7.0% and ≤6.5%) and sustained body weight reduction (≥5%) compared to placebo, semaglutide 1 mg, and insulin therapies in patients with type 2 diabetes.

For patients with Type 2 Diabetes, tirzepatide (5, 10, or 15 mg once weekly) offers significantly longer periods of stable blood sugar (HbA1c <7.0%) and sustained weight loss (≥5%) compared to placebo, semaglutide 1 mg, and insulin therapies. This suggests that tirzepatide may provide more durable disease management with fewer hypoglycaemic events than insulin.

A combined high-protein (25% energy) and low-glycemic-index (LGI) diet is superior to low-protein/high-GI diets for maintaining weight loss and improving insulin resistance (measured by TyG index) after an initial energy-restricted weight loss.

If you have recently lost weight, switch to a maintenance diet that is high in protein (around 25% of calories) and low in glycemic index (low-GI carbs). This specific combination helps you keep the weight off longer and improves insulin sensitivity better than diets low in protein or high in glycemic index. You do not need to count calories strictly; focus on the quality of your protein and carbohydrate sources.

Adopting a low-carbohydrate (LC) or very low-carbohydrate ketogenic (VLCK) diet (defined as <50g, 50-100g, or 101-150g carbohydrates per day) improves glycemic control and facilitates the deprescribing of antihyperglycemic medications in patients with Type 2 Diabetes Mellitus (T2DM).

If you have Type 2 Diabetes, reducing your daily carbohydrate intake to under 150 grams (and potentially under 50 grams for ketosis) can significantly improve your blood sugar levels and allow you to reduce or stop diabetes medications. Work with your doctor to adjust your insulin and other drugs to prevent low blood sugar, and ensure you are drinking enough water and getting electrolytes to avoid initial side effects like fatigue or cramps.

Type 2 Diabetes Mellitus can be put into remission (defined as HbA1c < 6.5% for ≥ 3 months without T2DM medications) through the use of therapeutic carbohydrate reduction and subsequent medication deprescription.

If you have Type 2 Diabetes, remission is possible. This means getting your blood sugar (HbA1c) below 6.5% for at least 3 months without taking diabetes medications. This is achieved by strictly limiting carbohydrates and working with your doctor to safely stop or reduce your diabetes drugs. It requires commitment to the diet and close monitoring.

A 12-week dietitian-led telehealth intervention using web-based applications reduces 24-hour systolic blood pressure by approximately 6.7 mmHg, achieving efficacy comparable to a self-directed approach using the same digital tools.

To lower your blood pressure, you can use a structured digital program. If you add weekly check-ins with a dietitian who helps you set goals and stay motivated, you may get an extra benefit in nighttime blood pressure and physical activity, but the core digital tools alone will still significantly lower your daytime blood pressure.

A dietitian-led telehealth intervention significantly reduces sleep (nocturnal) systolic and diastolic blood pressure more effectively than a self-directed digital approach.

If you want to improve your nighttime blood pressure, adding professional coaching to a digital health program is more effective than using the app alone. The dietitian support helps drive the lifestyle changes that specifically lower blood pressure during sleep.

Distributing a fixed weekly volume of resistance training across four sessions per week yields greater maximal strength gains than performing the same volume in a single session.

If you are an experienced lifter aiming to maximize your squat strength, split your weekly leg volume across four separate sessions (e.g., one heavy compound lift per day) rather than doing it all in one day. This allows you to handle heavier loads with better technique and less fatigue, resulting in significantly greater strength gains over 8 weeks compared to a single weekly session.

High-frequency (4x/week) and low-frequency (1x/week) resistance training produce equivalent improvements in muscle hypertrophy (muscle thickness) and jump height when weekly volume is equated.

If your primary goal is building muscle size (hypertrophy) or improving jump height, you do not need to train your legs 4 times a week. You can achieve similar muscle growth and power improvements by performing the same total volume of exercises in just one session per week. Focus on hitting your total weekly volume and intensity, regardless of how you split the sessions.

High effort (proximity to failure) is a necessary condition for muscle hypertrophy, particularly when using low loads, whereas high-load training inherently generates high effort.

To build muscle, you must train with high effort, meaning you should stop 0-3 reps before you physically cannot complete another repetition. This is true whether you are lifting heavy weights or light weights. If you use light weights, you MUST go close to failure to get similar growth as heavy weights.

Resistance exercise can be effectively performed using bodyweight, provided the intensity and effort are sufficient to overload the neuromuscular system.

You can build strength and muscle using only your body weight. Ensure you are performing exercises that challenge you (e.g., push-ups, squats) with sufficient intensity. If bodyweight exercises become too easy, increase the difficulty (e.g., elevate feet) rather than assuming you need weights.

Semaglutide (Ozempic/Wegovy) promotes significant weight loss (10-15% body weight) and improves glycemic control in adults with type 2 diabetes or obesity through GLP-1 receptor agonism, delayed gastric emptying, and appetite suppression.

Semaglutide is a once-weekly injection that mimics a gut hormone to slow digestion and reduce appetite. It is clinically proven to help people with obesity or type 2 diabetes lose 10-15% of their body weight when combined with diet and exercise. Side effects like nausea are common initially but often subside; starting with a low dose helps manage this. It is not a substitute for lifestyle changes but a tool to facilitate them.

Tirzepatide produces significantly greater weight loss than semaglutide and liraglutide in patients with obesity or type 2 diabetes.

If you are struggling with obesity or type 2 diabetes, tirzepatide (administered weekly at doses up to 15 mg) has demonstrated superior weight loss capabilities compared to semaglutide and liraglutide in clinical trials. To maximize results, combine this pharmacotherapy with lifestyle changes, including a caloric deficit, regular physical activity, and behavioral modifications.

Combining pharmacotherapy with lifestyle changes (diet, exercise, behavioral therapy) significantly enhances long-term weight loss maintenance and prevents weight regain.

Do not rely on medication alone for long-term weight management. Combine your prescribed pharmacotherapy with a balanced diet, regular physical activity, and behavioral interventions like cognitive-behavioral therapy. This integrated approach is essential for maintaining weight loss and preventing regain.

Isometric resistance training (e.g., handgrip) produces greater systolic blood pressure reductions (up to 8 mm Hg) than aerobic or dynamic resistance training.

Incorporate isometric exercises, such as handgrip training, into your routine. Perform 3 sessions per week, holding 30-40% of your maximum grip strength for 2 minutes with 1-minute rests, repeated 4 times. This specific type of exercise can lower blood pressure more effectively than aerobic or dynamic resistance training alone.

Sustained weight loss of at least 10% from maximum weight is recommended for adults with overweight or obesity at moderate or high ASCVD risk to reduce cardiovascular events.

If you are at moderate or high cardiovascular risk, aim to lose 10% of your maximum lifetime weight. This is a higher bar than the 5% target for lower-risk individuals, but it is the threshold shown to significantly reduce the risk of heart attacks and strokes. Discuss with your doctor if pharmacotherapy (like GLP-1s) or surgery is appropriate to help you reach this target.

GLP-1 receptor agonists (GLP-1RA) and related incretin mimetics (e.g., semaglutide, tirzepatide, retatrutide) produce significant weight loss in adults with obesity, achieving reductions comparable to bariatric surgery.

GLP-1 medications like Semaglutide and Tirzepatide are highly effective for weight loss, often achieving 15-24% body weight reduction, which rivals bariatric surgery. They work by increasing satiety and slowing digestion. Because obesity is chronic, these drugs likely need to be taken long-term to maintain weight loss. Side effects are mostly gastrointestinal (nausea), but serious risks exist for those with specific thyroid cancer histories. Consult a doctor to see if you are a candidate.

Lifestyle interventions, specifically achieving 7-10% body weight loss through caloric restriction and physical activity, are the cornerstone for reducing cardiovascular risk and improving hepatic steatosis in patients with metabolic-associated steatotic liver disease (MASLD).

To lower your heart and liver risk, aim to lose 7-10% of your body weight through a calorie-controlled diet (cut 500-1000 calories daily) and regular exercise (150 minutes of moderate activity weekly). Prioritize whole grains, lean proteins, and healthy fats (Mediterranean style), while eliminating sugary drinks and trans fats. Stop drinking alcohol completely, as it harms the liver more than it helps the heart in this condition. Work with a healthcare team to make these changes sustainable.

GLP-1 receptor agonists (specifically semaglutide and tirzepatide) produce substantial weight loss and metabolic improvements in patients with severe mental illness experiencing antipsychotic-induced weight gain, without exacerbating psychiatric symptoms.

For patients with severe mental illness struggling with antipsychotic-induced weight gain, GLP-1 receptor agonists like semaglutide offer a highly effective treatment option that reduces weight significantly without worsening mental health symptoms. While side effects like nausea are common, they are often mild and transient. The main barrier is often cost and insurance coverage, so patients and providers should advocate for access to these medications as a standard part of care for this population.

Orlistat (120 mg twice daily) produces a statistically significant weight reduction (>2.9% vs placebo) and improves cardiovascular risk factors in obese patients, including those with type 2 diabetes.

Orlistat is an approved option for weight loss that works by blocking fat absorption. To maximize results and minimize stomach issues, take 120mg twice daily with meals containing fat, but keep your overall fat intake moderate. You must also take vitamin supplements (A, D, E) separately from the drug to avoid deficiencies.